After discussing the limited evidence for additive benefit, he and his clinician start L-carnitine at 1 gram per day and CLA at a lower fraction of 3.2 grams per day
Insufficient time for the medication to work: While some people may notice changes in the first few weeks, it often takes longer for the full effects to become evident
SGLT2 inhibitors have shown cardiovascular benefits in patients with diabetes
AOD 9604 vs Tirzepatide: Summarizing Key Differences Fat Loss Mechanism AOD 9604: Direct lipolysis stimulation and lipogenesis inhibition Tirzepatide: Caloric deficit from appetite suppression plus metabolic optimization Appetite Impact AOD 9604: No significant effect Tirzepatide: Powerful suppression via GLP-1/GIP pathways Metabolic Pathway AOD 9604: Beta-3 adrenergic receptor activation (and likely additional pathways) in adipose tissue Tirzepatide: GLP-1 and GIP receptor agonism affecting glucose metabolism and insulin secretion Evidence Base AOD 9604: Primarily animal studies with mechanistic data Tirzepatide: Extensive human clinical trials with proven outcomes Timeline AOD 9604: 4-6+ weeks for visible effects in animal models Tirzepatide: Progressive weight loss documented across clinical trial periods over as long as 72 weeks How to Choose Between AOD 9604 and Tirzepatide Stop looking for the best peptide and start asking which mechanism addresses YOUR specific physiology
(Reference Arans, Edvardsson, Shevchouk, Zhang, Witley, Blid Skldheden, Zentveld, Vallf, Tufvesson-Alm and Jerlhag2023) reported that acute and repeated semaglutide treatment significantly decreased alcohol intake in both male and female rats, with more pronounced reductions in males, suggesting a potential link between alcohol intake and body weight ( P 30 kg/m 2 , n = 30) relative to placebo group
